| Susvimo (ranibizumab port delivery system) / Roche |
Archway, NCT03677934: A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration |
|
|
| Completed | 3 | 415 | US | PDS Implant filled with 100 mg/mL Ranibizumab, Intravitreal Injections of 10 mg/mL Ranibizumab | Hoffmann-La Roche | Neovascular Age-Related Macular Degeneration | 05/20 | 06/21 | | |
|
Pagoda, NCT04108156: This Study Will Evaluate the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Participants With Diabetic Macular Edema Compared With Intravitreal Ranibizumab |
|
|
| Active, not recruiting | 3 | 634 | US | PDS Implant Pre-Filled with 100 mg/mL Ranibizumab, Intravitreal Ranibizumab 0.5 mg Injection | Hoffmann-La Roche | Diabetic Macular Edema | 09/22 | 02/25 | | |
|
PAVILION, NCT04503551: A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm |
|
|
| Active, not recruiting | 3 | 174 | US | PDS Implant Pre-Filled with 100 mg/mL Ranibizumab, Intravitreal Ranibizumab 0.5 mg Injection | Hoffmann-La Roche | Diabetic Retinopathy | 10/22 | 05/24 | | |
|
Diagrid, NCT05126966 / 2021-003226-71: A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration |
|
|
| Withdrawn | 3 | 560 | Europe, RoW | Ranibizumab, Aflibercept, Port Delivery System with ranibizumab (PDS) | Hoffmann-La Roche | Neovascular Age-Related Macular Degeneration | 01/25 | 01/26 | | |
| Recruiting | 3 | 1000 | Europe, US, RoW | PDS Implant with Ranibizumab 100 mg/mL | Hoffmann-La Roche | Neovascular Age-Related Macular Degeneration | 12/26 | 12/26 | | |
NCT04657289 / 2020-001313-20: A Study of the Efficacy, Safety, and Pharmacokinetics of A 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome) |
|
|
| Recruiting | 3 | 442 | Europe, RoW | Ranibizumab, Port Delivery System with Ranibizumab | Hoffmann-La Roche | Neovascular Age-related Macular Degeneration (nAMD) | 12/26 | 12/26 | | |
NCT05562947: A Study Of The Efficacy, Safety, And Pharmacokinetics Of The Port Delivery System With Ranibizumab In Chinese Patients With Neovascular Age-Related Macular Degeneration |
|
|
| Recruiting | 3 | 68 | RoW | PDS with ranibizumab (100 mg/mL), Ranibizumab (10 mg/mL) | Hoffmann-La Roche | Neovascular Age Related Macular Degeneration, nAMD | 02/27 | 05/29 | | |
